Cerus Corporation Announces Pricing of Upsized Public Offering of Common Stock

About this update from Cerus Corporation

[{"type":"text","content":" CONCORD, Calif.--(BUSINESS WIRE)--\nCerus Corporation (Nasdaq: CERS) announced today the pricing of a registered underwritten public offering of its common stock for proceeds of approximately $55.0 million, before deducting estimated offering expenses payable by Cerus. The offering is expected to close January 31, 2020, subject to customary closing conditions. All of the shares sold in the offering were sold by Cerus. In addition, Cerus has granted the underwriter a 30-day option to purchase up to an additional $8.25 million of shares of its common stock. On January 28, 2020, the last sale price of the shares as reported on The Nasdaq Global Market was $4.15 per share.\n\n\nBTIG, LLC is acting as sole book-running manager for the offering.\n\n\nA shelf registration statement on Form S-3 (File No. 333-219727) relating to the shares of common stock described above was previously filed by Cerus with the Securities and Exchange Commission (\"SEC\") and declared effective on January 8, 2018. This offering is being made solely by means of a prospectus supplement and accompanying prospectus included in the registration statement. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. Alternatively, copies of the final prospectus supplement, when available, and the accompanying prospectus may be obtained by contacting BTIG, LLC at 65 East 55th Street, New York, NY, 10022, by email at [email protected] or by telephone at (212) 593-7555.\n\n\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.\n\n\nAbout Cerus\n\n\nCerus Corporation is dedicated solely to safeguarding the world’s blood supply. Based in Concord, California, Cerus develops and markets the INTERCEPT Blood System. Cerus currently markets and sells the INTERCEPT Blood System in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world.\n\n\nForward Looking Stat...

More updates from Cerus Corporation